Company Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:24:35 30/04/2024 BST 5-day change 1st Jan Change
0.34 SEK +2.72% Intraday chart for Lipigon Pharmaceuticals AB +3.03% -21.11%

Business Summary

Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.

Number of employees: 6

Sales per Business

SEK in Million2022Weight2023Weight Delta
Lipid-related Drugs
100.0 %
0 nan % 16 100.0 % -

Sales per region

SEK in Million2022Weight2023Weight Delta
Sweden
100.0 %
0 nan % 16 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 45 05/04/10
Chairman 67 31/12/11
Director of Finance/CFO 54 31/12/22
Chief Operating Officer 60 31/12/20
Comptroller/Controller/Auditor - -
Corporate Officer/Principal 59 31/12/19

Members of the board

Members of the board TitleAgeSince
Chairman 67 31/12/11
Director/Board Member 52 31/12/20
Director/Board Member 64 31/12/22
Director/Board Member 61 18/05/22
Director/Board Member 54 31/12/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 126,422,281 89,026,825 ( 70.42 %) 0 70.42 %

Company contact information

Lipigon Pharmaceuticals AB

Tvistevägen 48 C

907 36, Umeå

+46 7 05 78 17 68

http://www.lipigon.se
address Lipigon Pharmaceuticals AB(LPGO)
  1. Stock Market
  2. Equities
  3. LPGO Stock
  4. Company Lipigon Pharmaceuticals AB